Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Lenvatinib Following Progression on Immunotherapy Demonstrates Efficacy in Second-line HCC

January 20th 2023

Second-line lenvatinib may produce a survival benefit in patients with advanced hepatocellular carcinoma who have progressed on immunotherapy.

Early Exploration With HER-Vaxx Extends Survival for Patients with HER2+ Gastric/GEJ Adenocarcinoma

January 20th 2023

Patients with HER2-overexpressing metastatic or advanced gastric/gastroesophageal junction adenocarcinoma treated with HER-Vaxx plus standard-of-care chemotherapy had a statistically significant survival benefit compared with those who received chemotherapy alone.

Frontline Zolbetuximab/mFOLFOX6 Prolongs Survival in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

January 20th 2023

Frontline zolbetuximab plus mFOLFOX6 significantly improved progression-free and overall survival vs placebo/mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma, according to primary phase 3 data from the SPOTLIGHT trial.

Nivolumab Plus Ipilimumab or Chemo Maintains OS Benefit in ESCC in Long-Term Results

January 20th 2023

Nivolumab in combination with chemotherapy or ipilimumab maintained a clinically meaningful overall survival benefit vs chemotherapy alone in patients with treatment-naïve advanced esophageal squamous cell carcinoma.

Updated CheckMate-649 Data Support Nivolumab/Chemo as Frontline SOC in Advanced Gastric/GEJ/Esophageal Cancer

January 20th 2023

The combination of nivolumab (Opdivo) and chemotherapy continued to provide a clinically meaningful long-term survival benefit and deeper responses than chemotherapy alone in previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, according to 3-year follow-up data from the phase 3 CheckMate-649 trial.

Neoadjuvant Tremelimumab/Durvalumab Elicits Responses in Gastric/GEJ Adenocarcinoma

January 19th 2023

Neoadjuvant treatment with the combination of tremelimumab and durvalumab produced responses and was well tolerated in patients with mismatch repair–deficient and microsatellite instability–high, Epstein-Barr virus–negative gastric or gastroesophageal junction adenocarcinoma.

HER2-Low Classification Is Associated With Distinct Clinical Features in Advanced Gastric Cancer

January 19th 2023

Clinicopathological features of HER2-low advanced gastric cancer were distinct and distinguishable from those of HER2-positive or -negative disease, according to retrospective findings from a single-institution study that were presented at the 2022 Gastrointestinal Cancers Symposium.

Taking a Look Back at Trials From ASCO GI 2022

February 1st 2022

Reviewing some of the most talked about abstracts that were presented at the 2022 Gastrointestinal Cancers Symposium.

TST001 Under Evaluation in Locally Advanced or Metastatic Solid Tumors

January 23rd 2022

The safety and tolerability of TST001 is under investigation as a potential treatment option for patients with gastric/gastroesophageal junction cancer and other locally advanced or metastatic solid tumors as part of a phase 1 trial.

Nivolumab Plus mFOLFOX6 and Bevacizumab Misses PFS End Point in mCRC

January 23rd 2022

The addition of nivolumab to mFOLFOX6 and bevacizumab failed to demonstrate a statistically significant improvement in progression-free survival vs mFOLFOX6 and bevacizumab alone in previously untreated patients with metastatic colorectal cancer, according to findings from the phase 2/3 CheckMate 9X8 trial.

Trastuzumab Deruxtecan Demonstrates Sustained Efficacy in HER2+ mCRC

January 22nd 2022

Trastuzumab deruxtecan demonstrated durable responses and a safety profile that was consistent with findings from the primary analysis of the phase 2 DESTINY-CRC01 trial in pretreated patients with HER2-expressing metastatic colorectal cancer, according to updated results of the study.

Nivolumab/Encorafenib/Cetuximab Triplet Elicits High Response Rate in MSS, BRAF V600E-Mutant mCRC

January 22nd 2022

The addition of nivolumab to encorafenib and cetuximab elicited a high response rate and an acceptable safety profile in patients with refractory microsatellite stable, BRAF V600E–mutant metastatic colorectal cancer, according to findings from a phase 1/2 trial.

Regorafenib Plus Pembrolizumab Misses PFS End Point in Microsatellite Stable CRC

January 22nd 2022

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.

Pembrolizumab Triplet Induces Deep, Durable Responses in Some Patients With Treatment-Refractory mCRC

January 22nd 2022

The use of pembrolizumab plus binimetinib and bevacizumab in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer induced a median progression-free survival of 5.8 months, according to preliminary findings from a phase 2 trial.

Onvansertib Plus FOLFIRI/Bevacizumab Generates Meaningful Responses in KRAS-Mutant mCRC

January 22nd 2022

Onvansertib in combination with irinotecan, fluorouracil, and folinic acid, plus bevacizumab, demonstrated encouraging efficacy and was well-tolerated in patients with KRAS-mutated metastatic colorectal cancer.

Frontline Lenvatinib/TACE Improves OS in Advanced HCC

January 22nd 2022

Transarterial chemoembolization plus lenvatinib led to a significant improvement in overall survival vs lenvatinib alone as frontline therapy in patients with advanced hepatocellular carcinoma, according to findings from the phase 3 LAUNCH trial.

Dr. Oh on the Results of the TOPAZ-1 Trial in Advanced Biliary Tract Cancer

January 22nd 2022

Do-Youn Oh, MD, PhD, discusses the results of the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.

Dr. Hong on the Efficiency of the CodeBreaK 101 Trial in KRAS G12C-Mutated CRC and Other Solid Tumors

January 22nd 2022

David S. Hong, MD, discusses the efficiency of the ongoing phase 1/2 CodeBreaK 101 trial in KRAS G12C-mutated advanced colorectal cancer and other solid tumors.

Dr. Bekaii-Saab on the Updated Results of the KRYSTAL-1 Trial in KRAS G12C+ GI Cancers

January 22nd 2022

Tanios S. Bekaii-Saab, MD, FACP, discusses the updated results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C-mutated gastrointestinal cancers, including pancreatic ductal adenocarcinoma.

Olaparib Plus Pembrolizumab Demonstrates Manageable AEs in Advanced Cholangiocarcinoma

January 22nd 2022

The combination of olaparib and pembrolizumab demonstrated acceptable safety and an manageable adverse effect profile in patients with advanced cholangiocarcinoma who had received prior gemcitabine-based therapy, according to findings from a phase 2 trial.